Single Arm Feasibility of Multi-maintenance Olaparib After Disease Recurrence in Participants With Platinum Sensitive BRCAm High Grade Serous Ovarian Cancer

Trial Profile

Single Arm Feasibility of Multi-maintenance Olaparib After Disease Recurrence in Participants With Platinum Sensitive BRCAm High Grade Serous Ovarian Cancer

Recruiting
Phase of Trial: Phase 0

Latest Information Update: 11 Apr 2017

At a glance

  • Drugs Cediranib (Primary) ; Olaparib (Primary)
  • Indications Ovarian cancer
  • Focus Therapeutic Use
  • Acronyms MOLTO
  • Most Recent Events

    • 08 Apr 2017 Status changed to recruiting.
    • 09 Aug 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top